Stockscreener 앱 받기
323.50
0.59%
1.91
시간 외 거래:
323.50
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth? - The Globe and Mail
ALNYAlnylam Pharmaceuticals Inc Latest SEC Filings - Finviz
Price to book forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Enterprise value to revenue forward of Alnylam Pharmaceuticals, Inc – XETR:DUL - TradingView
Alnylam Pharmaceuticals (NASDAQ:ALNY): An Affordable Growth Stock with Explosive Momentum and a Reasonable Price - ChartMill
What Offers Alnylam Pharmaceuticals (ALNY) Sustained Long-Term Growth? - Yahoo Finance
Alnylam (ALNY) Has an RNAi Platform and TTR Franchise Bigger Than a One-Drug Biotech Label - AlphaStreet
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. - Yahoo Finance
Komodo Expands Strategic Partnership with Alnylam Pharmaceuticals, Inc. (ALNY) - Yahoo Finance
July 2026's Top Stocks Estimated To Be Trading Below Their Intrinsic Value - simplywall.st
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Expanding Its Enterprise-Wide AI Analytics Partnership - simplywall.st
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $370 to $527 - Moomoo
Canaccord reiterates Alnylam stock Buy rating after RNAi event By Investing.com - Investing.com Canada
Is Alnylam Pharmaceuticals (ALNY) Undervalued Following Its Expanded Komodo Health AI Partnership? - simplywall.st
ALNY Maintains Buy Rating -- Price Target Lowered by HC Wainwrig - GuruFocus
H.C. Wainwright cuts Alnylam stock price target to $470 on revenue estimates - Investing.com Canada
Barclays Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $527 - Moomoo
Alnylam Pharmaceuticals, Inc. (ALNY) Stock Analysis: A Biotech Powerhouse with a Potential 49.75% Upside - DirectorsTalk Interviews
Alnylam Pharmaceuticals (ALNY) Citi's Biopharma Back to School Conference Summary - Quartr
Number of shareholders of Alnylam Pharmaceuticals, Inc – BX:DUL - TradingView
Price to sales forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Enterprise value to EBITDA forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Alnylam Pharmaceuticals, Inc Actuals & Estimates (NASDAQ:ALNY) - TradingView
Alnylam Pharmaceuticals unveils 2030 targets, betting on AMVUTTRA and pipeline readouts - MSN
Biopharma bites: Ionis' rare disease deal, Vaxart's COVID-19 funding, Alnylam's AI embrace and more from Definium - FirstWord Pharma
Enterprise value to EBIT forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
ALNY Forecast — Price Target — Prediction for 2027 - TradingView
Alnylam Pharmaceuticals, Inc Shs Unsponsored Brazilian Depository Receipt Repr 0.05 Sh - TradingView
Alnylam Pharmaceuticals, Inc. (ALNY) Discusses ALN-6400 RNAi Therapy Targeting Plasminogen for Rare Bleeding DisordersSlideshow (NASDAQ:ALNY) 2026-06-25 - Seeking Alpha
Komodo Health Expands Strategic Partnership with Alnylam Pharmaceuticals to Scale Marmot Analytics Ai Platform - marketscreener.com
Alnylam Pharmaceuticals Inc RNAi Roundtable Webcast Transcript - GuruFocus
Price to earnings forward of Alnylam Pharmaceuticals, Inc. – NASDAQ:ALNY - TradingView
Komodo Expands Strategic Partnership With Alnylam to Scale AI-Powered Intelligence Platform - Business Wire
Oppenheimer Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $500 - Moomoo
Why (ALNY) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Morgan Stanley Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating, Maintains Target Price $370 - Moomoo
AI-Driven RNAi Push and Nordic Expansion Might Change The Case For Investing In Alnylam (ALNY) - simplywall.st
Alnylam Pharmaceuticals, Inc. (ALNY) and GENESIS Pharma Expand Commercial Partnership - Insider Monkey
Alnylam Pharmaceuticals (ALNY), Inceptive Form $2B Partnership to Advance RNAi Drug Discovery - Yahoo Finance
Regeneron gets US, EU review for myasthenia gravis drug (REGN) - Seeking Alpha
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - Sahm
Dyne Therapeutics adds ex-Sage CEO Barry Greene to board - Stock Titan
Alnylam (ALNY) Expands Its RNAi Therapeutics Reach Into Four More Nordic Countries - Insider Monkey
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Passes the "Little Book" Test with Explosive Growth and Upward Momentum - ChartMill
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Investor Outlook: A Biotech Leader with 56.90% Upside Potential - DirectorsTalk Interviews
Alnylam Pharmaceuticals, Inc. (ALNY) Partners with Inceptive Nucleics to Accelerate Growth as A High-Growth Large-Cap Stock - Insider Monkey
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY): A Decent Value Play with Strong Growth at a Discount to Peers - ChartMill
Alnylam Pharmaceuticals Inc (ALNY) Institutional Confidence - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Valuation: PE, PB & Fair Value Analysis - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alnylam Pharmaceuticals Inc (ALNY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alnylam Pharmaceuticals Inc - TradingKey
Does Alnylam’s Generative AI Pact With Inceptive Nucleics Redraw The R&D Bull Case For ALNY? - simplywall.st
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and Alnylam Pharma (ALNY) - The Globe and Mail
Alnylam expands Genesis Pharma collaboration in Europe - MSN
0.36%
자본화:
|
볼륨(24시간):